572 related articles for article (PubMed ID: 31816078)
21. Rheumatic immune-related adverse events from cancer immunotherapy.
Calabrese LH; Calabrese C; Cappelli LC
Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
[TBL] [Abstract][Full Text] [Related]
22. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
[TBL] [Abstract][Full Text] [Related]
23. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.
Benfaremo D; Manfredi L; Luchetti MM; Gabrielli A
Curr Drug Saf; 2018; 13(3):150-164. PubMed ID: 29745339
[TBL] [Abstract][Full Text] [Related]
24. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
25. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy.
Calabrese LH; Calabrese C
Curr Opin Rheumatol; 2020 Mar; 32(2):175-183. PubMed ID: 31922970
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
[TBL] [Abstract][Full Text] [Related]
27. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
[TBL] [Abstract][Full Text] [Related]
28. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.
Calabrese C; Kirchner E; Kontzias A; Velcheti V; Calabrese LH
RMD Open; 2017; 3(1):e000412. PubMed ID: 28405474
[TBL] [Abstract][Full Text] [Related]
29. Spectrum and impact of checkpoint inhibitor-induced irAEs.
Cappelli LC; Bingham CO
Nat Rev Rheumatol; 2021 Feb; 17(2):69-70. PubMed ID: 33235330
[No Abstract] [Full Text] [Related]
30. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
31. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
[TBL] [Abstract][Full Text] [Related]
32. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
[TBL] [Abstract][Full Text] [Related]
33. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
34. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
35. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
36. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.
Roberts J; Ennis D; Hudson M; Ye C; Saltman A; Himmel M; Rottapel R; Pope J; Hoa S; Tisseverasinghe A; Fifi-Mah A; Maltez N; Jamal S
Autoimmun Rev; 2020 Aug; 19(8):102595. PubMed ID: 32535092
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations.
Gremese E; Alivernini S; Ferraccioli ES; Ferraccioli G
Clin Immunol; 2020 May; 214():108395. PubMed ID: 32240819
[TBL] [Abstract][Full Text] [Related]
39. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
40. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
Abdel-Wahab N; Suarez-Almazor ME
Expert Rev Clin Immunol; 2024 Mar; ():1-21. PubMed ID: 38400840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
